Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae.
We made a comparative study of the in-vitro activities of grepafloxacin (GPFX), ofloxacin (OFLX), erythromycin (EM), clarithromycin (CAM), roxithro-mycin (RXM), and minocycline (MINO) against 20 strains of Mycoplasma pneumoniae (17 clinical isolates and 3 standard strains). The minimum inhibitory concentration (MIC)90-to-minimum bactericidal concentration (MBC)90 ratio showed that the new quinolones have bactericidal effects on M. pneumoniae. Thus, it is expected that the new quinolones, especially grepafloxacin, will be clinically useful antimicrobial agents for the treatment of M. pneumoniae infection because of their good pharmacokinetic properties and bactericidal action.
Ikejima
H
H
Department of Microbiology, St. Marianna University School of Medicine, Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. ike@marianna-u.ac.jp.
Yamamoto
H
H
Ishida
K
K
Kaku
M
M
Shimada
J
J
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D004341:Drug Evaluation; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones; D018942:Macrolides / Q000494:pharmacology*; D008911:Minocycline / Q000494:pharmacology*; D009177:Mycoplasma pneumoniae / Q000187:drug effects*; D010879:Piperazines / Q000494:pharmacology*; D015363:Quinolones / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D018942:Macrolides; D010879:Piperazines; D015363:Quinolones; D008911:Minocycline; C075375:grepafloxacin